Table 1 Patient demographic characteristics and response status at day 100 Post-Autologous Stem Cell Transplant (ASCT).
Overall | Overall (N = 186) |
|---|---|
Gender | |
Female | 65 (34.9%) |
Male | 121 (65.1%) |
AGE | |
Mean (SD) | 60.495 (8.731) |
Median | 62.5 |
Range | 36.0, 75.0 |
R-ISS Stage | |
I | 68 (42.8%) |
II | 73 (45.9%) |
III | 18 (11.3%) |
Missing | 27 |
High-risk cytogenetics | |
No | 150 (85.7%) |
Yes | 25 (14.3%) |
Missing | 11 |
High-risk “Plus” Cytogenetics | |
No | 143 (80.8%) |
Yes | 34 (19.2%) |
Missing | 11 |
IMWG Response criteria (at day 100) | |
Stringent Complete Response | 101 (54.3%) |
Complete Response | 18 (9.7%) |
Very Good Partial Response | 48 (25.8%) |
Partial Response | 16 (8.6%) |
Minimal Response | 1 (0.5%) |
Progressive Disease | 2 (1.1%) |
Binary response criteria | |
Complete Response | 119 (64%) |
Non-Complete Response | 67 (36%) |
Pet Interpretation (at day 100) | |
Negative | 111 (81.6%) |
Positive | 25 (18.4%) |
Missing | 50 |
MRD Negativity by sensitivity | |
Positive | 70 (37.6%) |
10−4 | 33 (17.7%) |
10−5 | 38 (20.4%) |
10−6 | 45 (24.2%) |
10−6 Sensitivity threshold | |
Negative | 45 (24.2%) |
Positive | 141 (75.8%) |
10−5 Sensitivity threshold | |
Negative | 82 (44.1%) |
Positive | 104 (55.9%) |
Consolidation therapy | |
No | 152 (81.7%) |
Yes | 34 (18.3%) |
Consolidation regimen | |
DRd | 13 (38.2%) |
IRd | 6 (17.6%) |
KRd | 6 (17.6%) |
Other | 9 (26.6%) |
Maintenance therapy | |
No | 30 (16.1%) |
Yes | 156 (83.9%) |
Maintenance regimen | |
PI Monotherapy | 8 (5.1%) |
PI Combination | 2 (1.3%) |
IMID-PI Combination | 26 (16.7%) |
IMID Monotherapy | 101 (64.7%) |
IMID Combination | 13 (8.3%) |
Other | 6 (3.9%) |
